Stocks · News reference
LABT stock has given up its prior gain. Lakewood-Amedex Biotherapeutics shares were trading higher after the company announced preclinical data in UTI and pulmonary infection indications in animal models treated with Bisphosphocin compounds.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lakewood-Amedex Says Nu-8 Shows Up To 97% Inhibition Of E. Coli Growth In Rodent Urinary Tract Infection Model
Lakewood-Amedex Biotherapeutics shares are trading higher after the company announced Minimum Inhibitory Concentration data from recent clinical isolates for its lead clinical candidate, Nu-3.